Sign in

BBLG on Nasdaq

Bone Biologics Corp

Bone Biologics Corp is an American orthopedic company that raised $729,000 in 2023 (SEC Form D).1 It is headquartered in Burlington, Massachusetts.1 Its shares trade on Nasdaq under the symbol BBLG.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Invacare, Avanos Medical or MSA Safety, or pick any stock.

  • TickerBBLG on Nasdaq1
  • IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies1
  • HeadquartersBurlington, Massachusetts1
  • Incorporated inDE2
  • Business address2 Burlington Woods Drive,, Suite 100,, Burlington, Ma 018032
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Division of Orthopedic Devices in a Pre-submission to support progression to a pivotal clinical trial in the United States.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2020

-0.1%Operating margin5
-0.2%Net margin5
0.0%Revenue growth, 20206

Where the money goes

Where each dollar of revenue went, fiscal 2020

  • Research and development0¢$340.7K
  • Other costs100¢$1.1B
  • Income tax0¢$1.6K

Out of $1.1B in revenue.65 The company lost money this year.

Financial statements

Revenue76$1.1B in 2020+0% since 2019
0$500.0M$1.0B$1.5B2019: $1.1B$1.1B20192020: $1.1B$1.1B2020+0%
Operating income65-$825.0K in 2020−66% since 2019
-$3.0M-$2.0M-$1.0M02019: -$2.4M-$2.4M20192020: -$825.0K-$825.0K2020−66%
Net income65-$1.8M in 2020−47% since 2019
-$4.0M-$3.0M-$2.0M-$1.0M02019: -$3.4M-$3.4M20192020: -$1.8M-$1.8M2020−47%

Every line of the income statement as filed: the last 2 fiscal years, latest first.10

Period ending2025-12-312024-12-31
Research and development$1.1M$2.1M
General and administrative$2.2M$2.1M
Total operating expenses$3.2M$4.2M
Loss from operations-$3.2M-$4.2M
Change in fair value of warrant liability$4.0K$51.1K
Interest income$122.0K$55.7K
Total other income$126.0K$106.7K
Net loss-$3.1M-$4.1M
Deemed dividend on warrant inducements-$3.2M
Net loss attributable to common stockholders-$3.1M-$7.3M
Weighted average shares outstanding - basic1.2M shares253.0K shares
Weighted average shares outstanding - diluted1.2M shares253.0K shares
Loss per share - basic-$2.65-$28.96
Loss per share - diluted-$2.65-$28.96

Compare Bone Biologics Corp with another company

Corporate structure

Bone Biologics Corp sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Bone Biologics Corp

  • INTRACOASTAL CAPITAL, LLC Filed SCHEDULE 13G/A on Bone Biologics Corp, latest Nov 7, 2025 (5 filings since Nov 27, 2023)
  • Lind Global Fund II LP Filed SC 13G/A on Bone Biologics Corp, latest Nov 14, 2024 (3 filings since Jun 26, 2023)
  • Ionic Ventures, LLC Filed SC 13G/A on Bone Biologics Corp, latest Jun 28, 2024 (5 filings since Oct 12, 2022)
  • Walleye Capital LLC Filed SC 13G/A on Bone Biologics Corp, latest Feb 14, 2024 (2 filings since Feb 14, 2023)
  • SABBY MANAGEMENT, LLC Filed SC 13G/A on Bone Biologics Corp, latest Jan 2, 2024 (2 filings since Jan 4, 2023)
  • Don Hankey Filed SC 13D/A on Bone Biologics Corp, latest Mar 29, 2023 (2 filings since Nov 1, 2021)
  • Bone Biologics Corp Burlington, Massachusetts
    • Inc. incorporated in the state of Subsidiary · California, United States

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Bone Biologics Corp reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Properties, in its own words

We lease our primary office, which is located at 2 Burlington Woods Drive, Ste 100, Burlington, MA 01803, on a month to month lease.

Item 2 of the 10-K filed Mar 2, 2026.4

Leadership

Who has led Bone Biologics Corp, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Neve Stephen R. La2015–2018
  2. Jeff Frelick2022–now

Chair

  1. Don Hankey2018–2023

President

  1. Amir F. Heshmatpour2008
  2. Neve Stephen R. La2015–2018

Chief financial officer

  1. Deina H. Walsh2015–now

Chief operating officer

  1. Jeff Frelick2015–2018
2010201520202025
Board members and other officers (15)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Inc. incorporated in the state of California3

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • Bone Biologics, Corp.Sep 25, 2014 to Nov 2, 20152
  • AFH ACQUISITION X, INC.Feb 1, 2008 to Sep 15, 20142

Timeline

  1. Sep 29, 20268-K Shareholder vote31
  2. Sep 16, 20268-K Listing notice or transfer32
  3. Jul 23, 20268-K Regulation FD disclosure33
  4. Jul 16, 20268-K Other events34
  5. Jul 9, 20268-K Entered a material agreement; Unregistered sale of shares; Other events35
  6. Mar 13, 20268-K Other events36
  7. Jan 8, 20268-K Regulation FD disclosure37
  8. Sep 4, 20258-K Regulation FD disclosure38
  9. Jun 30, 20258-K Entered a material agreement; Other events39
  10. Jun 26, 20258-K Other events40
  11. Jun 6, 20258-K Change to shareholders' rights; Bylaws or fiscal year changed; Other events41
  12. May 30, 20258-K Executive or director change; Shareholder vote42
  13. Feb 28, 2022New chief executive Jeff Frelick becomes CEO12
  14. Aug 19, 2015New chief executive Neve Stephen R. La becomes CEO13

Calendar

Coming up

  1. Nov 13, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.37) a share, on Nov 14, 2025.43

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

227 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 50 major events, 42 insider forms, 19 large holders, 1 private raises, 94 other. The latest 20:

  1. Oct 13, 202625-NSE EDGAR
  2. Sep 30, 20264 EDGAR
  3. Sep 30, 20264 EDGAR
  4. Sep 30, 20264 EDGAR
  5. Sep 30, 20264 EDGAR
  6. Sep 29, 20268-K EDGAR
  7. Sep 16, 20268-K EDGAR
  8. Aug 28, 2026DEF 14A EDGAR
  9. Aug 18, 2026PRE 14A EDGAR
  10. Aug 14, 202610-Q EDGAR
  11. Jul 24, 2026EFFECT EDGAR
  12. Jul 24, 2026424B3 EDGAR
  13. Jul 23, 20268-K EDGAR
  14. Jul 20, 2026DEFA14A EDGAR
  15. Jul 17, 2026S-3 EDGAR
  16. Jul 16, 20268-K EDGAR
  17. Jul 9, 20268-K EDGAR
  18. Jul 2, 2026ARS EDGAR
  19. Jul 2, 2026DEFA14A EDGAR
  20. Jul 2, 2026DEF 14A EDGAR

The 227 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

4 open-market trades by officers, directors and large owners since October 2021: 4 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 13, 2023Walsh Deina HChief Financial OfficerBuy8,000$0.64$5.1KForm 4
Sep 11, 2023Frelick JeffChief Executive OfficerBuy9,500$0.69$6.6KForm 4
Sep 6, 2023Walsh Deina HChief Financial OfficerBuy7,000$0.71$5.0KForm 4
Aug 31, 2023Frelick JeffChief Executive OfficerBuy7,600$0.66$5.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Jeffrey Frelick,60$300.0K$426.3K50
2025Deina Walsh,61$200.0K$263.1K50
2024Chief Executive Officer and President$300.0K$384.9K50
2024Chief Financial Officer$200.0K$242.4K50

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Nov 16, 2023Raised $729,000 in a private offering of equity Form D: 4 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Citadel Advisors LLC23,879$32.7K0.0%New
Tower Research Capital LLC (TRC)1,953$2.7K0.0%−2,173
SBI Securities Co., Ltd.230$3150.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Bone Biologics Corp is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBone Biologics Corp1
  • CIK0001419554
  • Employer ID (EIN)42-17434304
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address2 Burlington Woods Drive,, Suite 100,, Burlington, MA 018031
  • Phone(781) 552-44521
  • Shares outstanding2,756,057 as of Aug 14, 20269
  • Public float$7.2M as of Jun 30, 20254
  • AuditorWeinberg & Company, P.A, Los Angeles, California PCAOB ID 572; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceFeb 1, 20081
  • Filings484 in all: 4 (103), 8-K (102), 10-Q (54), 3 (22), CORRESP (21), 10-K (18), EFFECT (15), UPLOAD (15)1
    All 44 form types

    S-1/A (11), DEF 14A (10), SC 13G/A (10), SC 13D/A (9), POS AM (7), S-1 (7), SC 13G (7), 424B4 (6), 424B5 (5), NT 10-Q (5), S-3 (5), ARS (4), D (4), DEF 14C (4), DEFA14A (4), 10QSB (3), 4/A (3), PRE 14A (3), PRE 14C (3), S-1MEF (3), S-8 (3), NT 10-K (2), S-3/A (2), SC 13D (2), 10-K/A (1), 10SB12G (1), 25-NSE (1), 424B3 (1), 8-A12B (1), 8-K/A (1), CERT (1), D/A (1), DRS (1), DRSLTR (1), SCHEDULE 13G (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (10-K) Mar 2, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Aug 28, 2026
    Latest 8-K (8-K) Sep 29, 2026

Securities registered for trading

ClassSymbolExchange
Common stock, $0.001 par value per shareBBLGNasdaq
Warrants to Purchase Common stock, $0.001 par value per shareBBLGWNasdaq

From the cover page of the 10-K filed Mar 2, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks Bone Biologics Corp names in Item 1A of its 10-K filed Mar 2, 2026: 61 risks under these headings, as written.4

  • Risks Relating to Our Financial Position and Capital Needs
  • Our limited operating history makes it difficult to evaluate our current business and future prospects.
  • Our long-term capital requirements are subject to numerous risks.
  • Our recurring operating losses have raised substantial doubt regarding our ability to continue as a going concern.
  • We have incurred losses since inception and we expect our operating expenses to increase in the foreseeable future, which may make it more difficult for us to achieve and maintain profitability.
  • We face a number of risks associated with the incurrence of substantial debt which could adversely affect our financial condition.
  • Risks Related to the Development and Regulatory Approval of our Product Candidates
  • Our product candidates are at an early stage of development and may not be successfully developed or commercialized.
  • Any product candidates advanced into clinical development are subject to extensive regulation, which can be costly and time consuming, cause unanticipated delays or prevent the receipt of the required approvals to commercialize such product candidates.
  • Any product candidate we advance into clinical trials may cause unacceptable adverse events or have other properties that may delay or prevent their regulatory approval or commercialization or limit their commercial potential.
  • Delays in the commencement of clinical trials could result in increased costs and delay our ability to pursue regulatory approval.
  • Suspensions or delays in the completion of clinical testing could result in increased costs to us and delay or prevent our ability to complete development of that product or generate product revenues.
The other 51 risks
  • We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications for which there may be a greater likelihood of success.
  • We may find it difficult to enroll subjects in our clinical trials which could delay or prevent the start of clinical trials for our product candidate.
  • The results of preclinical studies are not necessarily predictive of future results. Our product candidates that may advance into clinical trials may not have favorable results in later clinical trials or receive regulatory approval.
  • Risks associated with operating in foreign countries could materially adversely affect our product development.
  • Failure to obtain regulatory approval in international jurisdictions would prevent our product candidate from being marketed abroad.
  • Even if our lead product candidate received regulatory approval, it may still face future development and regulatory difficulties.
  • The results of our clinical trials may not support our product candidate claims and the results of preclinical studies and completed clinical trials are not necessarily predictive of future results.
  • Risks Related to Our Dependence on Third Parties
  • We may fail to retain or recruit necessary personnel, and we may be unable to secure the services of consultants.
  • We rely on third parties to supply our raw materials, and if certain manufacturing-related services do not timely supply these products and services, it may delay or impair our ability to develop, manufacture and market our products.
  • We depend on third parties, including researchers, who are not under our control.
  • Business interruptions could adversely affect future operations, revenues, and financial conditions, and may increase our costs and expenses.
  • Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.
  • Risks Related to our Intellectual Property
  • We rely on patents and patent applications and various regulatory exclusivities to protect some of our product candidates, and our ability to compete may be limited or eliminated if we are not able to protect our products.
  • The terms of our patents may not be sufficient to effectively protect our product candidates and business.
  • We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights, as well as costs associated with lawsuits.
  • We cannot be certain we will be able to obtain patent protection to protect our product candidates and technology.
  • If we fail to comply with our obligations in the agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose rights that are important to our business.
  • We may infringe the intellectual property rights of others, which may prevent or delay our product development efforts, stop us from commercializing or increase the costs of commercializing our product candidates, and force us to pay damages.
  • We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed alleged trade secrets.
  • Our intellectual property may not be sufficient to protect our products from competition, which may negatively affect our business as well as limit our partnership or acquisition appeal.
  • If we are not able to protect and control our unpatented trade secrets, know-how and other technological innovation, we may suffer competitive harm.
  • We may incur substantial costs enforcing our patents, defending against third-party patents, invalidating third-party patents or licensing third-party intellectual property, as a result of litigation or other proceedings relating to patent and other intellectual property rights.
  • If we are unable to protect our intellectual property rights, our competitors may develop and market products with similar features that may reduce demand for our potential products.
  • Risks Relating to Commercializing of our Lead Product Candidate and Future Product Candidates
  • Our commercial success and ability to generate revenue depends upon attaining significant market acceptance of our lead product candidate and future product candidates, if approved, among physicians, patients, healthcare payors and treatment centers.
  • Even if we are able to commercialize our lead product candidate or any future product candidates, the products may not receive coverage and adequate reimbursement from third-party payors in the U.S. and in other countries in which we seek to commercialize our products, which could harm our business.
  • Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations.
  • Risks Related to Our Business Operations
  • We operate in a highly competitive environment.
  • Our future success is dependent, in part, on the performance and continued service of our officers and directors.
  • Competitors could develop and/or gain FDA approval of our products for a different indication.
  • We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.
  • The impact of public health crises is difficult to predict and could materially and adversely affect our business and results of operations.
  • Significant disruptions of information technology systems, computer system failures or breaches of information security could adversely affect our business.
  • We will need to grow the size of our organization in the future, and we may experience difficulties in managing this growth.
  • Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.
  • Our ability to use net operating losses to offset future taxable income may be subject to limitations.
  • Risks Related to Healthcare Compliance Regulations
  • Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings. If we or they are unable to comply with these provisions, we may become subject to civil and criminal investigations and proceedings that could have a material adverse effect on our business, financial condition and prospects.
  • The application of privacy provisions of HIPAA is uncertain.
  • Risks Related to Owning our Common Stock
  • The price of our common stock and public warrants may fluctuate substantially.
  • Future sales and issuances of our common stock or equity-linked securities could result in additional dilution of the percentage ownership of our stockholders and could cause our share price to fall.
  • There can be no assurance that we will be able to comply with the continued listing standards of Nasdaq, a failure of which could result in a delisting of our common stock and certain warrants.
  • We do not intend to pay cash dividends on our shares of common stock so any returns will be limited to the value of our shares.
  • The right of our President and Chief Executive Officer and Chief Financial Officer to participate in future financings of ours could impair our ability to raise capital.
  • If our shares of common stock become subject to the penny stock rules, it would become more difficult to trade our shares.
  • General Risk Factors
  • If we are unable to establish appropriate internal financial reporting controls and procedures, it could cause us to fail to meet our reporting obligations, result in the restatement of our financial statements, harm our operating results, subject us to regulatory scrutiny and sanction, cause investors to lose confidence in our reported financial information and have a negative effect on the market price for shares of our common stock.
  • We may be at risk of securities class action litigation.
  • Market and economic conditions may negatively impact our business, financial condition and share price.
  • If securities or industry analysts do not publish research or reports, or publish unfavorable research or reports about our business, our stock price and trading volume may decline.
  • Our Amended and Restated Certificate of Incorporation (“Certificate of Incorporation”) and our Amended and Restated Bylaws (“Bylaws”), and Delaware law may have anti-takeover effects that could discourage, delay or prevent a change in control, which may cause our stock price to decline.
  • Provisions of our warrants could discourage an acquisition of us by a third party.
  • Financial reporting obligations of being a public company in the U.S. are expensive and time-consuming, and our management will be required to devote substantial time to compliance matters.

Legal proceedings

In the normal course of our business, we may periodically become subject to various lawsuits. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, financial condition or cash flows. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
    SEC EDGAROther events
  35. 35
  36. 36
    SEC EDGAROther events
  37. 37
  38. 38
  39. 39
  40. 40
    SEC EDGAROther events
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50